PREDICTIVE ONCOLOGY INC (POAI)

US74039M3097 - Common Stock

1.34  -0.35 (-20.71%)

After market: 1.28 -0.06 (-4.48%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to POAI. POAI was compared to 187 industry peers in the Health Care Equipment & Supplies industry. POAI may be in some trouble as it scores bad on both profitability and health. POAI is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

POAI had negative earnings in the past year.
POAI had a negative operating cash flow in the past year.
POAI had negative earnings in each of the past 5 years.
POAI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -186.31%, POAI is not doing good in the industry: 90.32% of the companies in the same industry are doing better.
POAI's Return On Equity of -710.24% is on the low side compared to the rest of the industry. POAI is outperformed by 88.71% of its industry peers.
Industry RankSector Rank
ROA -186.31%
ROE -710.24%
ROIC N/A
ROA(3y)-80.65%
ROA(5y)-106.47%
ROE(3y)-112.04%
ROE(5y)-302.57%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of POAI (43.06%) is worse than 64.52% of its industry peers.
POAI's Gross Margin has declined in the last couple of years.
POAI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-1.93%

More info and screens

2

2. Health

2.1 Basic Checks

POAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
POAI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for POAI has been increased compared to 5 years ago.
The debt/assets ratio for POAI is higher compared to a year ago.

2.2 Solvency

POAI has an Altman-Z score of -37.84. This is a bad value and indicates that POAI is not financially healthy and even has some risk of bankruptcy.
POAI has a Altman-Z score of -37.84. This is amonst the worse of the industry: POAI underperforms 91.40% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that POAI is not too dependend on debt financing.
POAI has a Debt to Equity ratio of 0.10. This is comparable to the rest of the industry: POAI outperforms 59.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -37.84
ROIC/WACCN/A
WACC9.35%

2.3 Liquidity

POAI has a Current Ratio of 1.20. This is a normal value and indicates that POAI is financially healthy and should not expect problems in meeting its short term obligations.
POAI's Current ratio of 1.20 is on the low side compared to the rest of the industry. POAI is outperformed by 86.56% of its industry peers.
POAI has a Quick Ratio of 1.06. This is a normal value and indicates that POAI is financially healthy and should not expect problems in meeting its short term obligations.
POAI has a worse Quick ratio (1.06) than 74.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.2
Quick Ratio 1.06

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.00% over the past year.
POAI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.81%.
POAI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.77% yearly.
EPS 1Y (TTM)34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.46%
Revenue 1Y (TTM)-23.81%
Revenue growth 3Y12.51%
Revenue growth 5Y4.77%
Sales Q2Q%-51.94%

3.2 Future

Based on estimates for the next years, POAI will show a very strong growth in Earnings Per Share. The EPS will grow by 38.67% on average per year.
POAI is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.44% yearly.
EPS Next Y-1633.33%
EPS Next 2Y-4.08%
EPS Next 3Y38.67%
EPS Next 5YN/A
Revenue Next Year-90.58%
Revenue Next 2Y-20.59%
Revenue Next 3Y1.44%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for POAI. In the last year negative earnings were reported.
Also next year POAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

POAI's earnings are expected to grow with 38.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.08%
EPS Next 3Y38.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for POAI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PREDICTIVE ONCOLOGY INC

NASDAQ:POAI (1/8/2025, 8:23:15 PM)

After market: 1.28 -0.06 (-4.48%)

1.34

-0.35 (-20.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners4.33%
Inst Owner Change0%
Ins Owners1.7%
Ins Owner Change0%
Market Cap8.94M
Analysts43.33
Price Target3.06 (128.36%)
Short Float %2.01%
Short Ratio1.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-2.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.48
P/FCF N/A
P/OCF N/A
P/B 4.54
P/tB 5.12
EV/EBITDA N/A
EPS(TTM)-3.06
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-1.93
FCFYN/A
OCF(TTM)-1.93
OCFYN/A
SpS0.21
BVpS0.29
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -186.31%
ROE -710.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.06%
FCFM N/A
ROA(3y)-80.65%
ROA(5y)-106.47%
ROE(3y)-112.04%
ROE(5y)-302.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.24%
GM growth 5Y-1.93%
F-Score3
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.67%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.2
Quick Ratio 1.06
Altman-Z -37.84
F-Score3
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)49.73%
Cap/Depr(5y)37.75%
Cap/Sales(3y)38.79%
Cap/Sales(5y)29.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.46%
EPS Next Y-1633.33%
EPS Next 2Y-4.08%
EPS Next 3Y38.67%
EPS Next 5YN/A
Revenue 1Y (TTM)-23.81%
Revenue growth 3Y12.51%
Revenue growth 5Y4.77%
Sales Q2Q%-51.94%
Revenue Next Year-90.58%
Revenue Next 2Y-20.59%
Revenue Next 3Y1.44%
Revenue Next 5YN/A
EBIT growth 1Y10.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.03%
OCF growth 3YN/A
OCF growth 5YN/A